知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.015 秒)

    Zero order controlled drug delivery system
    4.
    发明申请
    Zero order controlled drug delivery system 审中-公开
    零级控制药物输送系统

    公开(公告)号：US20050106251A1

    公开(公告)日：2005-05-19

    申请号：US10484748

    申请日：2002-07-18

    申请人： John Langridge ,  Wei Tian ,  Olayinka Lawal

    发明人： John Langridge ,  Wei Tian ,  Olayinka Lawal

    IPC分类号： A61K9/28 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/16 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61K9/22 ,  A61K9/26

    CPC分类号： A61K9/2866 ,  A61K9/2846 ,  A61K9/2886 ,  A61K9/2893

    摘要： A controlled release dosage form comprising: (i) a tablet core comprising a pharmaceutically active ingredient and one or more pharmaceutically acceptable matrix forming polymers, (ii) a substantially insoluble casing extended over the tablet core covering between 25 to 99% of the surface area of the tablet core, like for example covering only the major surfaces like in FIG. 1 or on major surface and the sidewells like in FIG. 2, the casing resulting from electrostatic deposition of a powder comprising fusible particles onto the tablet core and fusing the particles to form a thin film such that the said electrostatic coated tablet releases the active ingredient with a release profile of active ingredient for 0 to at least 50% by weight release of active ingredient defined by the equations y=k*tn in which y is the fraction of active ingredient released, k is the kinetic constant, t is time, n is the release exponent and n is the range 0.70 to 1.0 i.e. an approximately zero order release profile.

    摘要翻译： 控制释放剂型，其包含：（i）片芯，其包含药物活性成分和一种或多种药学上可接受的形成基质的聚合物，（ii）在所述片芯上延伸的基本不溶性外壳，覆盖所述表面积的25至99％ 片状芯，例如仅覆盖如图1所示的主表面。 1或在主表面和侧壁上，如图1所示。 2，由将可熔颗粒的粉末静电沉积到片芯上并将该颗粒融合以形成薄膜的外壳，使得所述静电包衣片剂以活性成分的释放曲线将活性成分释放至0至少至少 50重量％的由式y = k * t 定义的活性成分的释放，其中y是释放的活性成分的分数，k是动力学常数，t是时间，n是释放 指数，n是0.70到1.0的范围，即约为零阶释放曲线。

    Fast disintegrating tablets
    5.
    发明申请
    Fast disintegrating tablets 审中-公开
    快速崩解片

    公开(公告)号：US20050169986A1

    公开(公告)日：2005-08-04

    申请号：US10505916

    申请日：2003-02-28

    申请人： Wei Tian ,  Ann Leighton ,  John Langridge

    发明人： Wei Tian ,  Ann Leighton ,  John Langridge

    IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

    CPC分类号： A61K9/0056 ,  A61K9/2077 ,  A61K9/2081

    摘要： A fast disintegrating tablet comprising an active ingredient and one or more disintegrants characterised in that the tablet comprises agglomerates having an agglomerated particle size of at least 50 μm, said agglomerates comprising at least 10% by weight of a superdisintegrant selected from croscarmellose cellulose, crospovidone and sodium starch glycollate and being free of active ingredient.

    摘要翻译： 一种快速崩解片剂，其包含活性成分和一种或多种崩解剂，其特征在于所述片剂包含具有至少50um的附聚粒度的附聚物，所述附聚物包含至少10重量％的选自交联羧甲纤维素纤维素，交聚维酮和 淀粉乙醇酸钠，不含活性成分。

    Sustained release ranolazine formulations
    6.
    发明授权
    Sustained release ranolazine formulations 有权
    持续释放雷诺嗪制剂

    公开(公告)号：US06369062B1

    公开(公告)日：2002-04-09

    申请号：US09538337

    申请日：2000-03-29

    申请人： Andrew A. Wolff ,  Fiona Baker ,  John Langridge

    发明人： Andrew A. Wolff ,  Fiona Baker ,  John Langridge

    IPC分类号： A61K3150

    CPC分类号： A61K9/2846 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/495 ,  A61K31/496 ,  Y10S514/964

    摘要： A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

    摘要翻译： 持续释放的雷诺拉嗪制剂含有雷诺嗪和部分中和的pH依赖性粘合剂的紧密混合物，以形成大部分不溶于低于pH4.5的水性介质中并可溶于高于pH 4.5的水性介质中的膜。 该制剂适用于每日两次给予雷诺嗪，并且可用于控制雷诺嗪的溶出速率，并维持人血浆雷诺嗪水平在550至7500ng / mL之间。

    Fast dissolving and taste masked oral dosage form comprising sildenafil
    8.
    发明申请
    Fast dissolving and taste masked oral dosage form comprising sildenafil 审中-公开
    包含西地那非的快速溶解和口味掩蔽的口服剂型

    公开(公告)号：US20060100214A1

    公开(公告)日：2006-05-11

    申请号：US10525680

    申请日：2003-08-20

    申请人： Wei Tian ,  John Langridge

    发明人： Wei Tian ,  John Langridge

    IPC分类号： A61K31/519 ,  A61K9/20

    CPC分类号： A61K9/2018 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/2013 ,  A61K9/2077

    摘要： A fast dissolving and taste masked sildenafil solid dosage form comprising: (i) sildenafil granules which granules comprise at least 45% by weight of a salt of sildenafil, a solubilisation inhibitor for said salt of sildenafil and optionally a sweetening agent and (ii) one or more disintegrants wherein the disintegrants or combination of disintegrants are present in the form of agglomerates having an average agglomerated particle size of at least 50 μm, said agglomerates comprising at least 10% by weight of disintegrant.

    摘要翻译： 一种快速溶解和口味掩蔽的西地那非固体剂型，其包含：（i）西地那非颗粒，其颗粒包含至少45重量％的西地那非盐，所述西地那非盐和任选的甜味剂的增溶抑制剂和（ii）一种 或更多的崩解剂，其中崩解剂或崩解剂的组合以平均聚集粒度为至少50μm的附聚物的形式存在，所述附聚物包含至少10重量％的崩解剂。